Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

6.9K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.9K
The Proteasome02:18

The Proteasome

7.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
7.7K
The Proteasome01:13

The Proteasome

1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
The Proteasome02:18

The Proteasome

3.9K
3.9K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
The Proteasome Structure01:17

The Proteasome Structure

2.2K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-Reported Mental Health and Desired Workplace Improvements Among Working Parents, United States, 2024.

Public health reports (Washington, D.C. : 1974)·2026
Same author

Community Assessment of Chemical Exposures After a Train Derailment-East Palestine, Ohio, and Darlington Township, Pennsylvania, February-March 2023.

Journal of occupational and environmental medicine·2026
Same author

Platelet mTOR Is a Regulator of Sterile Immunothrombosis.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

High and Increased Positive Public Opinions About Supports for Breastfeeding, United States, 2015-2024.

Public health reports (Washington, D.C. : 1974)·2026
Same author

Celebrating a year of ASH Scholar awardees.

Blood advances·2025
Same author

Functional classification of platelet gene variants using CRISPR HDR in CD34<sup>+</sup> cell-derived megakaryocytes.

American journal of human genetics·2025
Same journal

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026
Same journal

Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

The Journal of clinical investigation·2026
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K

Proteasome function is required for platelet production.

Dallas S Shi, Matthew C P Smith, Robert A Campbell

    The Journal of Clinical Investigation
    |July 26, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Proteasome inhibition blocks platelet production by impairing megakaryocyte proplatelet formation. Targeting RhoA signaling with ROCK inhibitors can restore platelet counts, offering a potential treatment for bortezomib-induced thrombocytopenia.

    More Related Videos

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    1.2K
    Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
    08:04

    Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

    Published on: June 10, 2025

    2.0K

    Related Experiment Videos

    Last Updated: Apr 26, 2026

    Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
    05:49

    Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

    Published on: November 29, 2024

    1.3K
    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    1.2K
    Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
    08:04

    Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

    Published on: June 10, 2025

    2.0K

    Area of Science:

    • Hematology
    • Cell Biology
    • Molecular Medicine

    Background:

    • Bortezomib, a proteasome inhibitor, treats multiple myeloma but causes thrombocytopenia.
    • The mechanism by which proteasome activity influences platelet production remains unclear.
    • Understanding proteasome's role in thrombopoiesis is crucial for managing treatment side effects.

    Purpose of the Study:

    • To investigate the impact of proteasome inhibition on megakaryocyte proplatelet formation.
    • To elucidate the molecular pathways involved in proteasome-mediated regulation of thrombopoiesis.
    • To explore therapeutic strategies for bortezomib-induced thrombocytopenia.

    Main Methods:

    • Pharmacologic proteasome inhibition in human and mouse megakaryocytes.
    • Analysis of megakaryocytes from mice deficient in PSMC1, a 26S proteasome subunit.
    • Inhibition of RhoA and Rho-associated protein kinase (ROCK) pathways.
    • Assessment of platelet counts in mouse models of induced thrombocytopenia.

    Main Results:

    • Proteasome inhibition blocked proplatelet formation in megakaryocytes.
    • PSMC1-deficient megakaryocytes and platelets led to severe thrombocytopenia and early lethality in mice.
    • Proteasome inhibition upregulated and hyperactivated RhoA, not NF-κB, impairing proplatelet formation.
    • Inhibition of RhoA or ROCK restored proplatelet formation in vitro and platelet counts in vivo.

    Conclusions:

    • Proteasome function is essential for normal thrombopoiesis and platelet production.
    • The RhoA/ROCK signaling pathway mediates the inhibitory effects of proteasome dysfunction on platelet formation.
    • Targeting RhoA signaling presents a promising therapeutic approach for managing thrombocytopenia in patients treated with bortezomib.